Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If one reads the thread the subject was "Marketing" and specifically Marketing ActiPatch in the US.
FDA definition for a Repackager: Packages finished devices from bulk or repackages devices made by a manufacturer into different containers (excluding shipping containers).
Both Scott and SAI preform this function. Scott has an additional component as they brought DJO in to do the Marketing.
IMO, BIEL is supplying KT with a finished product in retail packaging ready to sell so they don't do any 'Repackaging'.
Some still don't understand the OEM Business Plan
BIEL no longer "Markets" ActiPatch in the USA.
KT Tape, DJO Global, SAI Brands have taken over ActiPatch Marketing in the US.
BIEL manufactures the ActiPatch Device and sells them to KT/DJO/SAI.
That's it, BIEL is done.
KT, DJO, SAI do the Marketing to consumers.
KT is almost up to speed in the US having purchased 21,000 lbs of the Devices and placing product in thousands of CVS Stores. KT also started selling their ActiPatch product, Recovery+ Wave, in the UK last month.
DJO has been selling their ActiPatch Enhanced 'EME Knee/Back Wrap' Products online for 6 months.
SAI has yet to launch but they are developing an extensive product line covering ever joint in the body.
We have been through this before
The role of a OEM Supplier is a behind the curtain gig.
The 'OEM Principle' is the public face while the 'OEM Supplier' exchanges notoriety for a steady cash flow.
BIEL wants to make their OEM Partners look as good as possible in order to sell more product.
If public information, FDA, US Customs, ect., is shared on a message board by shareholders it does not violate OEM NDA restrictions.
Apparently the following company company communications were missed:
* Quarterly Sales Growth, KT Health and DJO Launches Outpacing Forecasts
APRIL 19, 2021 BLOG, NEWS, PRESS RELEASES 0 COMMENTS IANWAR@BIELCORP.COM
FREDERICK, MD, April 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire —
BioElectronics Corporation (https://www.bielcorp.com/ OTC PINK: BIEL) is pleased to report Q1 2021 revenue figures, the progress on three different product launches into the OTC and medical markets, ongoing efforts to expand international distribution, and finally, new initiatives into strengthening R&D/manufacturing capabilities.
First quarter sales were $605,675 which is 18% higher than Q4 2020 sales, and an impressive 73% of total 2020 revenue; these percentage increases not only document the Company’s strong growth, but also serve as objective evidence of effectiveness for the Company’s strategic repositioning as an OEM manufacturer. The Q1 2021 sales figure is robust, as there is over $306,000 of deferred sales incoming from signed contracts, for products that have yet to be shipped.
Looking ahead, the Company is now working with their three major channel partners, i.e., KT Health and Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market, to solidify new orders after strong initial product launches that took place in Q1 2021. Kelly Whelan, President & CEO, expressed enthusiasm, “Initial OTC feedback has been very positive, as witnessed by strong consumer reviews (averaging over 4.5 out of 5 on Amazon.com and their company websites) for both the KT Recovery+ Wave™ and DonJoy® EME products. The launch into the medical channel was slowed by the pandemic but has recently accelerated as hospitals are resuming non-emergency surgical procedures.”
The Company is also pushing forward on the international sales front. In addition to re-acquiring their CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which now allows for product distribution in Canada, Australia, and New Zealand. Ms. Whelan also said, “We are now exploring expanding our OTC sales into more countries in the EU using the same strategy of identifying firms with strong retail experience selling their branded products into the retail market. We hope to be able to announce the results of these conversations in the near future. In addition, through Medi-Launch, we have signed four new international distributorships contracts for our RecoveryRx line.”
Mr. Richard Staelin, Chairman of the Board, commented, “We believe it is important to keep investing in one of our core capabilities, i.e., designing and manufacturing Pulsed Short Wave Therapy medical devices. With this in mind, we are in active talks to conduct new clinical trials both with our RecoveryRx product and extensions of our OTC devices. We are also working with our contract manufacturer to strengthen our manufacturing capabilities to accommodate for increased production, amid international volatility in raw material costs.”
* 3/11/2021
Fellow Shareholders,
We have been seeing lots of comments and receiving lots of questions about advertising and promotion.
As you are aware, we have shifted the focus of BioElectronics Corporation. We are now operating as an OEM in the over-the-counter retail space. We manufacture devices- we do not market, advertise or promote.
In the past year, we built the KT Recovery+ Wave to the specifications of the customer- color, battery life, package design, etc. We have also manufactured devices for use in the DJO Advantage Line back and knee wraps.
The Recovery+ Wave product “officially” launched on February 22nd. The product is currently being placed on shelf in CVS stores. We have no expectation that KT Health would spend money advertising or promoting the product until the shelf placements are complete. That would simply make no sense. We have been informed that DJO is currently crafting their marketing and advertising campaign. As with most multi-billion dollar companies, things simply don’t happen quickly at DJO.
The simple fact of the matter is that we do not advertise, promote or market the over-the-counter retail products. As an OEM, our profit is made when we sell the devices to each marketing partner.
We do not set wholesale or retail pricing and we have no direct contact with the retail buyers.
Simultaneously, we have been building a contract sales force to promote the technology and the brand name RecoveryRx to the medical professional’s market- physical therapy, surgeons, pain doctors and the like.
I thank each of you for being a shareholder. Our team appreciates your support.
Kelly Whelan
President
BioElectronics Corporation
* 3/3/2021
From BIEL. Many of you over the years have asked for a spokesperson for products:
Super proud to have paralympian and world champion Oksana Masters promoting the KT Recovery+ Wave (manufactured by BioElectronics Corporation) #teambiel #TeamUSA #innovation #neuromodulation #electroceuticals #rollout #drugfreepainrelief #sportsmedicine #otc #fdacleared #onshelf
* Release #:812-197420-rl-1190694:
BioElectronics Corporation Announces Substantial Increase in 4th Quarter 2020 Revenue; Major Convertible Debt Holders Agree to Forego Interest in 2021
Frederick, Maryland, Jan. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (OTC PINK:BIEL) is pleased to report that Q4 revenue for 2020 exceeded $519,000, representing an increase of 241% when compared to Q3 revenue in 2020 ($151,956). Correspondingly, Q4 2020 revenue represents an increase of 233% when compared to the cumulative revenue of Q1 and Q2 in 2020 ($155,818).
As of today, the Company has $554,074 in deferred revenue remaining on the books, at least half of which is scheduled to ship in Q1 of 2021.
Richard Staelin, Ph.D., Chairman of the Board, said, “We believe this increase in both revenue and deferred revenue is a strong signal that the firm is moving in the right direction.” He attributes this robust growth to the firm’s unique portfolio of products and the management’s decision to prioritize partnerships with entities that have a strong brand recognition and significant retail presence.
Keith Nalepka, VP of Sales, commented: “We are pleased with the increase in revenue and look forward to the national retail rollout of KT Recovery+Wave™ and the DonJoy® Advantage products, Powered by ActiPatch®. We are simultaneously bringing on more international distribution channels and ramping up our efforts to market and sell the RecoveryRx® brand domestically.”
The managers of the firm’s two largest lenders, which are both controlled by Whelan family members, Ibex LLC and St. John’s LLC, have agreed to extend foregoing of interest due on their convertible debt notes through the end of 2021. Kelly Whelan, President & CEO of BioElectronics, stated: “It is the goal of both BioElectronics’ management team and the Whelan family to bring the Company to profitability as swiftly as possible, for the benefit of all shareholders. The Whelan family has collectively foregone interest in excess of $750,000 in 2020, and will extend this hiatus on interest collection through at least 2021.”
Dr. Staelin noted that “the Board is deeply appreciative of the Whelan family foregoing any interest in 2020 and 2021. This decrease in interest expenses coupled with a steady increase in sales will bring the firm much closer to its goal of posting profits in the near future.”
* BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market
DECEMBER 15, 2020 BLOG, NEWS, PRESS RELEASES
BioElectronics Executes Distribution Agreement with KT Health, LLC for North American Retail Market FREDERICK, MD, Dec. 15, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — BioElectronics Corporation (OTC PINK: BIEL), (www.bielcorp.com) is pleased to announce that it has executed an OEM agreement with KT Health, LLC to bring its innovative pain management devices to encompass retail and e-commerce distribution throughout North America, as well as several additional key international markets.
The agreement incorporates BioElectronics’ ActiPatch® technology into KT Health’s KT Recovery+® product line, which will be marketed under the proprietary trade name KT Recovery+ Wave™. KT Health will leverage BioElectronics’ FDA 510(k) clearance to market, promote, and distribute the devices for the treatment of general musculoskeletal pain. As part of this agreement BioElectronics will cease active promotion of the brand name ActiPatch in North America. Existing channel partners in the USA will continue promoting the ActiPatch brand name, while BioElectronics will continue expanding its network of international distributors for ActiPatch.
Keith Nalepka, VP Sales and Marketing for BioElectronics, said, “This is an amazing win for our Company. KT Recovery+ Wave™ combines our drug-free pain relief technology with the brand power and adhesives expertise of the recognized leader in drug-free pain treatment and recovery. Consumers will be able to easily place the KT Recovery+ Wave™ device anywhere on the body to treat musculoskeletal pain. We believe KT Health is an excellent match for our technology and can effectively leverage its large customer base that is already comfortable with wearables.”
Greg Venner, CEO of KT Health, commented, “We are extremely pleased to be partnering with BioElectronics on such an innovative and effective product. KT Recovery+ Wave™ allows KT Health to broaden our drug-free pain relief options, expanding our product line into the chronic pain category. We look forward to a long and productive partnership with BioElectronics.”
* THANKSGIVING LETTER FROM THE CHAIRMAN
November 26th, 2020
Dear Shareholders,
It has been a few months since I wrote a Chairman’s letter laying out our new OEM strategy that we implemented just about a year ago. The purpose of this letter is to document some of our accomplishments over the last 12 months and to share with you some of the major events that have occurred, or we believe will be occurring in the early part of 2021.
Sales
Soon after the management reorganization, our sales team got on the phones to re-establish relationships with firms that the Company had talked to over the last few years. After a few false starts, the team re-engaged with three firms with interest of selling our medical devices into the domestic OTC market. The first was Scott Specialty. This firm was in the process of developing specialty wraps for DonJoy. Scott placed their first order in August and we anticipate that the final units associated with this initial order will be delivered by early December. (DonJoy is already selling units online and we are told they will be placing units in brick and mortar outlets next month.) We are anticipating a new order from Scott just after the new year.
Two other firms have also placed orders to sell our device in the domestic OTC market. However, they have yet to distribute their products into retail and thus we are not able to identify them. With this noted, both will be receiving delivery of units in December and thus we anticipate booking sales to these customers in fourth quarter 2020. (These two customers anticipate selling into their retail markets in first quarter 2021.)
Internationally, we landed a contract with Adcock, a large firm in South Africa. Adcock is now in the process of registering the product and first sales to them should occur in early 2021. In addition, now that we have re-acquired our CE mark, we are able to reopen communications with our international distributors. We anticipate (or have already received) new orders from Romania, Italy, Australia, Sweden, the UK, and Spain. These sales should be booked in 4th quarter 2020 or 1st quarter 2021. In addition, one of our major domestic customers has been talking to us about also acquiring distribution internationally. These talks will probably continue into 2021.
Finally, we are in the early stages of selling into the medical professional channel with our RecoveryRx product. The plan is to use a 300+ salesforce of independent reps. This salesforce is being set up by Medi-Launch, a firm that has expertise in forming medical salesforce teams and launching new medical products. We have already signed up over 275 salespeople who have distributed more than 1500 samples to surgeons and other medical professionals. These samples allow the medical professionals evaluate our product for post-surgical pain and wound care, the claim associated with our non-OTC 510 (k). A few sales have already been booked and ultimately, we believe this channel of distribution could account for as much as 15% of our total sales volume.
Although I suspect most of you are primarily interested in the above information on sales (and ultimately profits) I would briefly like to mention the support activities that have occurred over this time period to make all these sales happen.
Modifying the product design and building up production capability. One of our customers wanted major design changes to our 720 hour device. This required extensive internal design changes to the device and modifications of the manufacturing processes. In addition this customer wanted to completely redesign the packaging. Coordinating all these changes resulted in extensive communications with the customer’s design team (and their top management) as well as nightly calls to our overseas manufacturer. There were surprisingly few bumps in the road and we are well on the way to fulfill their order. Importantly, this experience has greatly enhanced our core capabilities in product design and manufacturing.
Regulatory issues
We started off the year with significant regulatory issues. The regulatory team worked tirelessly with the firm, NEMCO, to get re-certified. It was a long battle, but we received notification in early November. This certification was critical as it allows us to again sell internationally.
I wish this was the only regulatory issue that we faced this year. We also need to get another certification, called MDSAP. This certification will allow us to sell in Canada and Australia among other countries. The short story is that we are well positioned to complete all the audits needed for certification by late January 2021. In the process we have developed a totally new inventory tracking system needed to augment our quality control processes. Development of this system has been a total team effort.
Other issues—Salesforce sales, Rebranding and R&D
Three other efforts that are currently in progress deserve mention. The first involves developing systems to handle sales through our new salesforce network and new marketing and training materials to support this salesforce. The training materials have been developed and are being used in numerous training zoom meetings, where we educate the independent sales reps on how to present the information concerning our device.
This new emphasis on selling our Rx product has also led us to revise our branding strategy so as to better differentiate the RecoveryRx device from the ActiPatch device. This rebranding is particularly important because the sales prices for these two devices are quite different. Our current plan is to discontinue North American sales under the brand name of ActiPatch by the end of the year. OTC sales in North America will be under the brand names of our marketing partners- essentially a license and supply agreement. We will retain the ActiPatch brand for units embedded into an appliance and sold under the appliance manufacturer’s brand name as “Powered by ActiPatch.”
Last, but not the least, we have made good progress with our R&D efforts. We started basic research to ascertain how our device affects brain waves. This project could open up the doors to solving numerous other diseases/ailments. We have also received notification that our neck study paper has been accepted for publication. The results reported in this paper not only show efficacy of the device over NSAID’s but also strong evidence supporting our claim that our device works via central sensitization. This latter finding is very useful when talking to medical professionals, since they want to know the “mechanism of action”, i.e., why our device works.
Summary
In summary, it has been a busy and productive year. The Company is moving in the right direction. Numerous new systems have been developed to support our new OEM strategy. Our core capabilities of R&D and expertise in designing and manufacturing Pulsed Short Wave Therapy devices have increased. The forecast for the next year has us above breakeven sales. Meeting these projections will not be easy, but it is doable. I am sure there will be some bumps, but the BIEL team will rise to the challenge and come out stronger. Thank you for your continued support, have a great Thanksgiving and stay safe.
* BioElectronics Earns CE Mark for the ActiPatch and RecoveryRx -- Drug-Free Pain Therapy Devices, Opens the Sales Market for 33+ Additional Countries
FREDERICK, MD, Nov. 12, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that it has received the CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx® Pulsed Shortwave Therapy (PSWT) medical devices.
The ActiPatch is indicated for the treatment of general musculoskeletal/soft-tissue pain, while the RecoveryRx is indicated for the treatment of postoperative pain. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark.
Keith Nalepka, VP Sales and Marketing for BioElectronics, said: “This is the latest in a series of wins for the Company. The CE mark will allow us to resume fulfilling substantial orders for existing international partners, and close pending deals that were contingent on the CE mark. We are excited that 2021 will be a great year of sales for the Company.”
The certification for the CE mark is valid until May 2024, and the Company’s updated quality management system will ensure prompt recertification.
* BioElectronics’ ActiPatch® Therapy To Be Marketed By DonJoy® Advantage
NOVEMBER 6, 2020 BLOG, NEWS, PRESS RELEASES
FREDERICK, Md., Nov. 6, 2020 /PRNewswire/ — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.comis pleased to announce the execution of a commercial partnership agreement with Scott Specialties Inc (SS http://scottspecialties.com/) to bring their innovative pain management devices to the retail consumer healthcare marketplace under the DonJoy® (DJO www.djoglobal.com) Advantage product line.
This commercial partnership will leverage the ActiPatch’s broad indications for use and offer an active-passive treatment combination product to treat pain, increase physical functionality and improve overall quality of life. The new products will be marketed under DJO’s DonJoy Advantage (DJA) line of orthopedic appliances and sold as an EME Knee Wrap and an EME Back Wrap, “powered by ActiPatch“. In January 2020, BioElectronics obtained a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the drug free ActiPatch® medical device, for the indication: “adjunctive treatment of musculoskeletal pain.” With the latest clearance, ActiPatch remains the only pulsed shortwave therapy (PSWT) device with an over-the-counter clearance for treating any form of musculoskeletal pain.
Keith Nalepka, VP Sales and Marketing for BioElectronics expressed his enthusiasm for the market opportunity: “This is a great opportunity for the ActiPatch brand. We have executed on our OEM strategy by partnering with Scott Specialties this past spring and leveraging their relationship with DJO to drive ActiPatch sales. During the pandemic we have seen consumers continuing to seek alternatives to oral medicines for pain. By partnering with Scott Specialties and another soon-to-be-announced, major sports medicine company, we are confident that these innovative product offerings will meet the need for a growing demand.” Kelly Whelan, President of BioElectronics, stated “We are thrilled to have the marketing strength of DonJoy Advantage coupled with the power of ActiPatch in products available to consumers online now at www.donjoyperformance.com. A soft launch in retail outlets is scheduled for December and the products will be promoted by DJO’s sales force in Q1, 2021.”
* Release #:812-190762-rl-1190694:
Richard Staelin, Ph.D. Rejoins the Board of BioElectronics Corporation
FREDERICK, MD, June 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioElectronics Corporation (BIEL), www.bielcorp.com, the maker of non-invasive electroceutical devices, announced today that it has appointed Richard Staelin, Ph.D. as the Chairman of the Board following the resignation and retirement of Ms. Patricia Whelan.
“The management team at BioElectronics thanks Patricia Whelan for her service and appreciates her willingness to stay on until a qualified replacement accepted a board position following the death of Andrew Whelan, the founder of BioElectronics Corporation,” said Keith Nalepka, Vice President of Sales.
"We are pleased to welcome Dr. Staelin as an independent director and Chairman to BioElectronics Corporation’s board. Dr. Staelin rejoins BioElectronics at an exciting time as we continue to drive our OEM strategy forward and build deeper relationships with current international distributors to fulfill our purpose of helping people live pain free. We are confident he will provide valuable perspective as we continue to execute our strategy, drive profitability and enhance value for all shareholders. We look forward to his contributions and are excited to welcome him back,” said Kelly Whelan, CEO.
Richard Staelin stated, “I look forward to again chairing the board at BioElectronics and helping to guide the firm to reach its enormous upside potential. Recently, Kelly Whelan and Keith Nalepka have taken over the management of the firm and not only have they shown strong leadership, they developed a new long-term vision for the firm. In addition, Dr. Koneru has been providing the technical expertise needed to help foster new product development. I see my challenge as helping the firm focus on actions that will quickly bring the Company to financial independence by building on BioElectronics’ core capability of a deep knowledge of Pulsed Short Wave Therapy (PSWT). The team is focused on building synergistic strategic alliances to facilitate efficient distribution of the Company’s products into North America while simultaneously working to develop new products aimed at mitigating chronic and acute pain.”
About Dr. Staelin: Richard Staelin is the Edward and Rose Donnell Professor of Business Administration at The Fuqua School of Business, Duke University. He served as Associate Dean for Faculty Affairs at The Fuqua School from 1984 until July 1991. For the next two years, he was Executive Director of Marketing Science Institute in Cambridge, Massachusetts. After that he served as Managing Director of The Fuqua School's Global Executive MBA program (GEMBA) 1995-1997, Associate Dean for Executive Education 2000-2002, Co-Director of the Teradata Center for Customer Relationship Management at Duke University 2000-2005, and Deputy Dean 2002-2004. As of July 1, 2004, he stepped down from his administrative duties to devote all his attention to research and teaching. Subsequent to that he was one of the initial members of BiVarus, a start-up that utilized his research on patient experience data and its relationship to the quality of health care.
* BioElectronics Announces FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain
FEBRUARY 3, 2020 BLOG, EVENT, NEWS, PRESS RELEASES
FREDERICK, MD- February 3, 2020 – BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to announce that it has obtained a new 510(k) clearance from the U.S. Food and Drug Administration (FDA). This new, over-the counter marketing clearance was granted for the drug free ActiPatch® medical device, for the indication: “adjunctive treatment of musculoskeletal pain.”
The ActiPatch was already FDA-cleared for over-the-counter treatment of pain from knee osteoarthritis and plantar fasciitis (heel pain) in 2017. The latest clearance expands these indications to cover all musculoskeletal pain complaints. Keith Nalepka, VP Sales and Marketing, expressed confidence on exploiting the expanded market opportunity: “The expanded clearance paves the way for new products to be marketed with approved medical claims for musculoskeletal pain in the back, knee, hips, wrists, elbow, ankle etc.”
Kelly Whelan, President of BioElectronics, stated “The Company intends to capitalize on this new clearance by offering additional products to retail channel partners, in alignment with our 2020 strategy to prioritize the OEM (Original Equipment Manufacturer) aspects of our business.” With the latest clearance, ActiPatch remains the only pulsed shortwave therapy (PSWT) device with an over-the-counter clearance for treating any form of musculoskeletal pain.
The 510(k) application was prepared by the R&D team comprising: Kenneth McLeod, Ph.D., Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D., Gregory Mario and Jeremy Mario Professor, Duke University, Ian Rawe, Ph.D., Director of Clinical Research, BioElectronics and Sree Koneru, Ph.D., VP Product Development, BioElectronics.
Thanks Tazzer, The Wave Printing Press is Rolling Out Product Once Again
21,500 lbs of Recovery+ Wave in the last 6 months!
Important to remember that this information is obtained from US Customs Documents.
Any Shipments going direct from BIEL's Factory to ROW are not being tracked.
Go BIEL !!!
Go KT Tape !!!
Thanks Hawk. Women's Health is a major influencer
"Since it launched in 2005, Women's Health has been a trusted, award-winning source of information on the latest health, fitness, weight loss, nutrition, and beauty news and trends. Serving more than 36 million readers each month across all of its platforms, Women's Health seeks to empower readers with tips and insights from the latest health and wellness research and leading experts in the field—but presented in a fun, engaging way that helps readers lead happier, healthier lives. The print magazine is published 10 times a year by Hearst Magazines, while the website and social extensions of the brand post new content multiple times a day."
https://www.womenshealthmag.com/about/a24170223/about-womens-health/
This is the Ivivi Sofpulse, been around since 2008
Ivivi shut down many years ago. A company, Rio Grande Neuroscience, purchased the human end of the business and Assisi took over the Veterinarian end of Sofpulse.
In 2017 Endonovo purchased Sofpulse from Rio Grande for $4 million.
ENDV has done zip with Sofpulse. Take a look at their ihub message board.
The Sofpulse only has prescription FDA Clearance.
At $299 for 8-10 days of therapy that has to be a hard sell for a disposable product.
William Monn is not "Kelly's friend", He is VP of Production
Monn, Dr. Sree Koneru, John Martinez, and Erin Sanders exercised 'Stock Options' that were a part of their BIEL employee compensation package.
All of these people are long term BIEL employees that contributed to BIEL's rising SP and deserve the 'Options'.
BIEL's International Partners have begun Consumer Education
This one is from Romania.
Manage Pain With Electromagnetic Pulse Therapy
June 6, 2021
Electromagnetic pulse therapy uses low-level electromagnetic radiation to relieve pain in the bones and muscles, being a non-invasive and painless method. ActiPatch is an advanced therapy for osteoarticular and muscle pain associated with osteoarthritis pain and arthritis pain caused by various injuries and inflammations. ActiPatch Pulsed Shortwave Therapy is based on the pulsation of electromagnetic energy with radio frequency in the body and is useful in all types of musculoskeletal pain - acute and chronic.
Pain is a vast subject and can be caused by a massive variety of factors that can affect both physiology and neurology. One of the reasons why pulsed electromagnetic field therapy works effectively for pain management and pain relief is that it not only provides symptomatic pain relief, but also aims to address the root causes of pain. When used regularly, it improves cell energy and reduces inflammation.
Electromagnetic pulse therapy is fast becoming a non-invasive method of addressing chronic pain and injury and is unique in its ability to combat the factors that cause chronic pain, genetic and aging problems, and in its unique ability to reduce pain and inflammation.
Take advantage of the benefits of this therapy today and get rid of pain simply and for a long time!
http://olt.ro/2021/06/06/gestioneaza-durerea-cu-o-terapie-cu-impulsuri-electromagnetice/
LOL,Another Biased Opinion, Facts Show the Truth
KT Tape KT Recovery+ Wave Electromagnetic Pain Relief Device
Visit the KT Tape Store
4.3 out of 5 stars 123 ratings
https://www.amazon.com/KT-Tape-Recovery-Electromagnetic-Relief/dp/B08WTN6V2Y
KT RECOVERY+ WAVE™
$34.99
Free shipping on ALL orders over $50
4.4 star rating
199 Reviews
https://www.kttape.com/collections/kt-tape-products/products/kt-recovery-wave
LOL, Ask 1000 people what PEMF is and 999 will give you a blank stare
<<<<<<<<<<<<< PEMF isn’t new >>>>>>>>>>>>>>>>>
The accurate history of PEMF can be found at this link, BIEL gets several mentions, https://en.wikipedia.org/wiki/Pulsed_electromagnetic_field_therapy
BIEL's first FDA 510k Clearance was in 2002, prescription only eyelid surgery. A few Plastic Surgeons heard about it.
The next 510k Clearance was in 2017 for Knee OA and Plantar Fasciitis. This was the first 'Over the Counter' FDA Clearance. BIEL finally had a chance to Market to 320 million Americans but did not have the money to do so.
3 Years later BIEL has New Management, New BOD, New OEM Business Plan, and most importantly an FDA OTC Full Body Musculoskeletal 510k Clearance. This is where the BIEL 2.0 clock starts ticking.
One year after Full Body Clearance, BIEL's goal since its inception in 2000 and impeded by a Global Pandemic, BIEL has Partnered with Market Icons KT Tape and DJO Global.
These established companies have the clout and capital to educate consumers on the benefits of non-drug PEMF pain relief and make it easily available in stores across the US.
The bottom line is the dollar value of shares not the number
<<<<<<<<<<< billions of shares on the ask >>>>>>>>>>>>>
At BIEL's current .0029 SP and $63.75 million Market Cap 1 billion shares has a dollar value of $2.9 million, less than 4.6% of the Market Cap.
During the recent Reddit Run:
1/26 - from .0023 to .0039, 66% rise on a Volume of 426 million shares.
2/11 - from .0048 to .0074, 52% rise on a Volume of 465 million shares.
During the FDA OTC Run:
02/06/2017 - .0005 to .0015, 200% rise on a Volume of 1.42 billion shares.
No problem with SP appreciation during these periods of very large Volume.
Saying BIEL is doomed because it has 24 billion shares is like saying you can't afford a trip to Japan because a Big Mac costs 381 Yen, not bothering to research the exchange rate which is 110 Yen = 1 US dollar.
Why Would BIEL Need a "100 Pack" ActiPatch option for Customers?
New GUDID Listings
ActiPatch - 00851329005494
ActiPatch Muscle and Joint Relief Therapy 100 pack
Company Name: Bioelectronics CorporationVersion or Model: 088
ActiPatch - 00851329005487
ActiPatch Knee Pain Relief Therapy 100 pack
Company Name: Bioelectronics CorporationVersion or Model: 088
ActiPatch - 00851329005470
ActiPatch Back Pain Relief Therapy 100 pack
Company Name: Bioelectronics CorporationVersion or Model: 088
Institution Sales must have driven this new product listing on the NIH Global Unique Device Identification Database.
https://accessgudid.nlm.nih.gov/devices/search?query=pqy
LOL, a 6.4 million share .003 Ask disappears after 3.2 million Buys
Hello 31 !!!
One has to read the disclaimer at the bottom
<<<<< Everything I say and write is my opinion and my opinion only >>>>>>
No Facts just Opinions.
LOL, KT & Amazon Customer Data Disagrees with You
Amazon Website
KT Tape KT Recovery+ Wave Electromagnetic Pain Relief Device
Visit the KT Tape Store
4.3 out of 5 stars 109 ratings
KT Website
KT RECOVERY+ WAVE™
$34.99
Free shipping on ALL orders over $50
4.4 star rating
198 Reviews
https://www.kttape.com/collections/kt-tape-products/products/kt-recovery-wave
Some clarification on the BIEL/MM relationship
IMO the MMs do not have a target painted on BIEL's back.
MMs are in business to make $$$, they can do this as a stock goes up or down.
The larger MMs cover thousands of companies. They program their computers to trade in a certain manner based on historical and other data.
BIEL breaks out of its current algorithm by:
* Becoming Profitable
* Adding more Partners like KT Tape and DJO Global
* Reducing Debt
* Up Listing to the OTCQB Exchange, only takes a .01 SP
* Up Listing to the OTCQX Exchange, only takes a .10 SP
* Upgrades to their Credit Report
* Higher Trading Volumes make Manipulation more Difficult
The Broker Dealers/MMs do what ever will make them the most money
The first important thing to understand is that retail customers Sell to and Buy from the MMs. They are a middle man that takes a cut of every transaction.
The MM mandate is to always provide a Bid & Ask Price so that traders can always Sell shares that they own or Buy shares that they want to own.
MMs are supposed to keep an inventory of every stock that they cover.
What happens if there is high demand for a stock? The MMs can either let the SP rise to a level where legitimate share owners are willing to Sell or they can Sell 'Phantom Shares' that do not exist.
If they Sell 'Phantom Shares' the SP will need to drop to below their Selling price or they lose money when they Cover the Naked Short and MMs don't lose money as they control the Game.
If the Celadon story that was in my last post was read you could see one of many scams that Broker Dealers/MMs can use to steal money from investors.
Here is the scam per the SEC:
"The SEC's order finds that, from at least July 2016 through December 2017, certain broker-dealer customers of Celadon routinely used their accounts held at Celadon to liquidate large volumes of shares in thinly-traded, low-priced, over-the-counter stocks held by their own customers. According to the order, Celadon facilitated its broker-dealer customers' sales into the market by executing short sales throughout the day in a principal capacity. Celadon covered its short positions at the end of the day by buying the same number of shares from the broker-dealer customers at a lower price, also on a principal basis. During this period, the order finds, the trading gains that Celadon generated based on the price differences between the short sales to the market and the shares purchased from its broker-dealer customers accounted for almost one-third of the firm's revenue. The order further finds that, for at least ten thousand of these short sales, Celadon failed to locate shares of those stocks that it could borrow, as is required by the federal securities laws."
https://www.sec.gov/enforce/34-89404-s
75% of today's Volume was FTD, 47 million out of 62 million shares. Was that all legitimate "Market Making" or was the MM trying to cap the SP. Retail investors have no way of knowing.
This is not about long term Naked Shorting
Broker Dealers/MMs have up to 13 days to close out their Naked Shorting before they get sanctioned.
That is plenty of time to Manipulate a SP and then Cover the Shorting or as some of the below examples show just do whatever and see if you get caught.
"Compliance with Regulation SHO began on January 3, 2005. Regulation SHO was adopted to update short sale regulation in light of numerous market developments since short sale regulation was first adopted in 1938 and to address concerns regarding persistent failures to deliver and potentially abusive “naked” short selling."
"Due to continued concerns about failures to deliver, and to promote market stability and preserve investor confidence, the Commission has amended Regulation SHO several times since 2005 to eliminate certain exceptions, strengthen certain requirements and reintroduce the price test restriction."
"Although the vast majority of short sales are legal, abusive short sale practices are illegal. For example, it is prohibited for any person to engage in a series of transactions in order to create actual or apparent active trading in a security or to depress the price of a security for the purpose of inducing the purchase or sale of the security by others. Thus, short sales effected to manipulate the price of a stock are prohibited."
SEC Charges Brokerage Firm with Short Sale Violations
July 27, 2020
https://www.sec.gov/enforce/34-89404-s
SEC Brings “Naked Short Selling” Case
Thursday, May 27, 2021
https://www.natlawreview.com/article/sec-brings-naked-short-selling-case
Morgan Stanley Agrees to Pay $5 Million for Reg SHO Violations
Washington D.C., Sept. 30, 2020
https://www.sec.gov/news/press-release/2020-238
FINRA FINES MERRILL LYNCH FOR SHORT SALE REPORTING DEFICIENCIES
JULY 23, 2020
https://financefeeds.com/finra-fines-merrill-lynch-short-sale-reporting-deficiencies/
Rule 204 – Close-out Requirement. Rule 204 requires brokers and dealers that are participants of a registered clearing agency[8] to take action to close out failure to deliver positions. Closing out requires the broker or dealer to purchase or borrow securities of like kind and quantity. The participant must close out a failure to deliver for a short sale transaction by no later than the beginning of regular trading hours on the settlement day following the settlement date, referred to as T+4. If a participant has a failure to deliver that the participant can demonstrate on its books and records resulted from a long sale, or that is attributable to bona fide market making activities, the participant must close out the failure to deliver by no later than the beginning of regular trading hours on the third consecutive settlement day following the settlement date, referred to as T+6. If the position is not closed out, the broker or dealer and any broker or dealer for which it clears transactions (for example, an introducing broker)[9] may not effect further short sales in that security without borrowing or entering into a bona fide agreement to borrow the security (known as the “pre-borrowing” requirement) until the broker or dealer purchases shares to close out the position and the purchase clears and settles. In addition, Rule 203(b)(3) of Regulation SHO requires that participants of a registered clearing agency must immediately purchase shares to close out failures to deliver in securities with large and persistent failures to deliver, referred to as “threshold securities,” if the failures to deliver persist for 13 consecutive settlement days.[10] Threshold securities are equity securities[11] that have an aggregate fail to deliver position for five consecutive settlement days at a registered clearing agency (e.g., National Securities Clearing Corporation (NSCC)); totaling 10,000 shares or more; and equal to at least 0.5% of the issuer's total shares outstanding. As provided in Rule 203 of Regulation SHO, threshold securities are included on a list disseminated by a self-regulatory organization (“SRO”). Although as a result of compliance with Rule 204, generally a participant’s fail to deliver positions will not remain for 13 consecutive settlement days, if, for whatever reason, a participant of a registered clearing agency has a fail to deliver position at a registered clearing agency in a threshold security for 13 consecutive settlement days, the requirement to close-out such position under Rule 203(b)(3) remains in effect.
22s are Printing
Thanks Hawk, 197 Reviews after 5 months is a record breaker for KT
KT has many products that have been on the market for years and are still in the double digits with their Review count.
KT knows that they have a big $$$$ product with The Wave.
Everyone is entitled to an opinion
IMO, the previous CEO was a 'my way or the highway' kind of guy. This caused lost opportunities for BIEL.
Starting in 2020 that attitude was gone.
Dr. Staelin, a respected Professor of Marketing, brought back to the BOD as Chairman.
Keith Nalepka, 15 years experience selling Medical Products, appointed to the BOD.
The realization that BIEL does not have the resources to Educate and Market to 320 million Americans, followed by the switch to a OEM Business Plan.
BIEL achieves an 18 year goal of FDA Clearance for a Full Body OTC ActiPatch.
OEM Agreements reached with 3 companies, that we know of probably more, to market ActiPatch Enhanced Products in the US.
This is an amazing turnaround, especially when one understands that it was accomplished during the worst Global Pandemic in the last 100 years, Trillions of dollars lost to business disruptions around the world .
What has changed in 10 years that now brings success to BIEL?
<<<<<<<<< I was left holding a $50,000 dollar bag for 10 years >>>>>>>>>
* BIEL redesigns ActiPatch to its current water resistant style 2014
* ActiPatch FDA Reclassification to 'Class 2' reduces regulations 2015
* ActiPatch FDA Cleared for Foot & Knee use 2017
* Keith Nalepka joins BIEL as Sales VP 2017
* New Management brings new ideas to BIEL 2019
* RecoveryRx FDA Cleared for Post-Op Pain 2019
* Dr Staelin rejoins and Keith Nalepka joins BIEL BOD 2020
* New Business Plan, OEM Supplier 2020
* ActiPatch FDA Cleared for OTC Full Body use 2020
* BIEL granted CE Mark opening sales to 36 countries 2020
* KT Tape begins Sales of the Recovery+ Wave BIEL OEM Product 2021
* DJO Global begins Sales of the EME Wraps BIEL OEM Product 2021
* SAI Brands new OEM Partner for 10 BIEL OEM Products 2021
BIEL is a very different company than it was 10 years ago.
The 20 Pallet Shipment is from BIEL's Manufacturer, CICD
<<<<<<<<<< How would you know what KT has ordered? >>>>>>>>>>>>>
It went direct from CICD's China factory to KT's HQ in Utah.
CICD is FDA Registered as 'Contract Manufacturer' of 'NONTHERMAL SHORTWAVE THERAPY DEVICE' for BIEL.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm
The Bill of Lading states only one commodity in the shipment, 'ELECTRICAL NERVE STIMULATORS TOTAL 20 PLTS'.
KT is currently only selling 1 product that it gets from BIEL, the Recovery+ Wave.
LOL, Ask Price went from 24 to 27 in 4 minutes
Time..Last Price..Last Size..Bid Price..Ask Price
13:06:19 ET 0.0027 21816 0.0026 0.0027
13:05:15 ET 0.0026 50000 0.0026 0.0027
13:05:10 ET 0.0026 1683515 0.0024 0.0026
13:03:41 ET 0.0026 500 0.0025 0.0026
13:03:21 ET 0.0025 2010000 0.0025 0.0026
13:03:17 ET 0.0025 454000 0.0023 0.0025
13:02:53 ET 0.0024 10000 0.0024 0.0025
13:01:49 ET 0.0024 1096746 0.0023 0.0024
13:00:55 ET 0.0023 10000 0.0023 0.0024
13:00:17 ET 0.0023 10000 0.0023 0.0024
LOL, "Someone else" is the CEO of BIEL
<<<<<<< I find is strange that he himself did not post a clarification on this, instead someone else did >>>>>>>
If someone feels that the CEO of BIEL is publicly presenting false information about a BIEL VP and member of the BOD please present your misgivings to the SEC and FINRA.
"Kelly Whelan
22h ·
Keith is in his office. He has not left the Company."
"Kelly Whelan
please see page 11 https://backend.otcmarkets.com/.../financi.../283495/content Keith is HOLDING his shares. Also see page 6- showing additional CASH investments by Keith, Rick and myself."
Page 6 New Loans, Q1 2021 Disclosures
5/12/2020 $ 53,635 $ 50,000 $ 3,635 5/13/2022 K. Nalepka Keith Nalepka Operating Loan
5/19/2020 $ 26,762 $ 25,000 $ 1,762 5/20/2022 K. Nalepka Keith Nalepka Operating Loan
Page 11 Company Insiders Stock Holdings, Q1 2021 Disclosures
Keith Nalepka VP of Sales & Marketing Leesburg, VA 100,000,000 Common
Stock
The Reddit Day Traders Pushed the SP Up in late January/February
Day Traders rarely stick around very long hence the name.
The Reddit Push began on 1/25, moving BIEL up 13% from .0021 to .00237, on 122 million in Volume.
The biggest gains came on 1/26, up 66% to .004 on 426 million shares, and 2/11 up 52% to .0074 on 465 million shares.
.0074 was the highest Closing Price, the 8s were all Intra Day moves never holding until the Close
BIEL had closed at .0021 on the 4 trading days prior to the Reddit Interest and we closed at .002765 today long after the Reddit Crew has moved on.
This was not a case of BIEL Fundamentals changing and investors selling, it was a case of Day Traders moving into BIEL for a quick profit and moving on.
Today it took a Fake News story about KN and 26 million shares Shorted to move BIEL down 1.2 percent.
http://regsho.finra.org/FORFshvol20210602.txt
LOL, Like no one has been working from home for the last year due to the Global Pandemic
<<<<<<<<< streaming a Zoom call doesn’t count as “in office” >>>>>>>>>>
Pew Research
"Most workers who say their job responsibilities can mainly be done from home say that, before the pandemic, they rarely or never teleworked. Only one-in-five say they worked from home all or most of the time. Now, 71% of those workers are doing their job from home all or most of the time."
https://www.pewresearch.org/social-trends/2020/12/09/how-the-coronavirus-outbreak-has-and-hasnt-changed-the-way-americans-work/
Just another episode in the long running series, 'What Fake News Can We Dream Up to Damage BIEL'
# 127 KN has Quit BIEL ..... confirmed False
# 64 BIEL to Declare BK .... confirmed False, but still has reruns
# 44 SEC to Shut Down BIEL .... confirmed False
# 32 BIEL to RS Any Day ..... confirmed False, but still has reruns
# 38 No FDA for ActiPatch .... confirmed False
# 51 No FDA OTC for ActiPatch .... confirmed False
# 83 No FDA Full Body for ActiPatch .... confirmed False
# 101 BIEL to Increase AS Any Day .... confirmed False, but still has reruns
It looks like the perpetrators of today's Fake News have lost their, 'Be Very Afraid', no Sells in the last 2 hours, 19 Buys, back to 29.
LOL, 4 million share Buy at 3:54 at 29
And a 50k share Sell @ 3:59:36 drops the SP to 28. Total BS Manipulation.
Buys = 7.88 million shares
Sells = 3.266 million shares
Thanks Nina, Colfax held an Investor's Day to explain the split
The DJO presentation starts on page 52
https://ir.colfaxcorp.com/static-files/e1d3fe0f-b6a2-4eb0-bdfe-30cdcb040a5f
Colfax is a very aggressive company and has grown quickly through acquisitions. They are selling 14 million shares to generate cash for debt reduction/expansion and selling their Air/Gas Handling business which will bring in $1.8 billion.
Lets check the Facts
The FDA studied PEMF/PSWT for several years and in 2015 created a new Product Code, PQY, to more accurately identify PEMF/PSWT Products. This PQY Product Code reclassified PEMF/PSWT from a Class 3 Device to a Class 2 Device. This opened the door for a Over the Counter Clearance.
In 2017 BIEL submitted a 510k application with Clinical Data proving Safety and Efficacy. The FDA Cleared ActiPatch for Knee and Foot OTC use.
In 2020 BIEL submitted new Clinical Data to expand ActiPatch use to the Full Musculoskeletal System. The FDA agreed and granted ActiPatch Clearance for Full Body OTC use.
Thanks for your Opinion but I will trust the FDA's Opinion that ActiPatch is a Safe and Effective Pain Reliever.
All Straw Man arguments addressed many times on this Board
Investors are waiting for the next Q results, and if they seriously increase sales or not. I'm sure Kelly will "pre announce" if they are good (but how good). Whatever the number some will say it is not good enough
too many shares, too many noteholders, many due in this years second half. BIEL financed Five FDA Clearances with the current debt, they are now monetizing those Clearances
Many pink investors don't think BIEL can sustain sales, I agree. DJO, KT Tape, SAI Brands and their combined 175 years of Medical Device experience disagree with your opinion
Many investors aren't impressed with the volatility (classic pink flipper) and the current management (the family run scam). We all know how this share structure is abused. New management, New BOD, New COB, New OEM Business Plan, New OEM Partners, New CE Certification, New Post-Op Clearance, New Full Body Pain Clearance, a lot of Positive changes and excellent results
The lack of reporting on time (except for Q1) on a consistent basis.
Plus the OTC Yield signs on a consistent basis. Financial Statement was on time, the Atty Letter was late, took OTC Markets 10 days to clear Yield sign after letter submitted.
Many investors see this as a dead sector, which it is. BIEL is too late with too little for the game. LOL, the Global Pain Relief Market was worth 65 Billion in 2020
If BIEL can't even finish in the top 10 at the FDA Opioid Challenge why would the professional investor care about this junk? There were 250 entrants in the Challenge, there was no 'Top 10', there were 2 Grants given out for each of the 4 categories, Pfizer also entered and and received no Grant, none of the Grants were given to OTC products
The simple answer Pinhigh is giving investors a reason to Buy BIEL Shares which increases Buying Volume.
The MMs operate by programing trading algorithms into their computers. The goal of which is to make money. They don't care if these profits are made while a stock is rising or falling as long as they are earning as much as possible on each move.
The MMs loved the recent Reddit generated BIEL excitement with its 400 million share trading days. While the high Volume made it difficult to manipulate the SP they made big dollars on the transaction fees and Buy/Sell spread.
IMO, to be a sustainable SP rise it needs to be based on increased Sales and Profits.
Announcements of FDA news, OEM Partnerships, Distributors are all great and show forward momentum but unless they are followed up with substantial increases in revenue and profit investors lose their enthusiasm.
The exception would be a Partnership with a major Player which included large amounts of BIEL compensation spelled out in the PR.
BIEL's Day is coming it is just taking longer than anticipated. When it arrives the MM's computers will be happy to watch the BIEL SP soar while raking in $$$$ from the High Trading Volume.
MMs can Sell their Phantom Shares at the Bid or Ask Pricing
If they transact at the Bid Price they are considered a 'Sell'.
If they Transact at the Ask Price they are considered a 'Buy'.
BIEL is Trading with a .003 Bid and a .0031 Ask.
An order hits the MM for 1 million Shares with a Limit Price of .003 .
The MM fills it with his own Phantom Shares and pockets the $3,000 .
Ever wonder why your Bid Order that has been languishing for hours did not get filled? An MM gave his Orders priority over yours.
An order hits the MM for 1 million shares with no Limit or a .0031 Limit Price.
The MM fills it with his Phantom Shares and pockets the $3,100.
Ever wonder why your Order to Sell at the Ask Price took so long or never was executed? An MM gave his Orders priority over yours.
If Reg SHO Daily Report is "meaningless" why did the SEC and FINRA implement it to try and control Rampant Naked Shorting?
<<<<<<<<<<<<<< Short Volume"s meaningless >>>>>>>>>>>>>>>
<<<<<<< Just MMs doing their job filling orders during the day >>>>>>>>
Market Makers have 14 Days to Cover their Shorting before they suffer any significant consequences.
This is plenty of of time to drive a SP Down with Naked Short Selling, under the guise of 'Making a Market', and then Cover the Short at a Lower SP making a Handsome Profit.
The MMs Sold Short 21 million shares on Friday, 80% of the Day's Total Volume, and these are Phantom Shares that the MMs did not Own and did not Borrow.
Does anyone really believe that they had to do this to 'Make a Market'?
That there would not have been BIEL Shares available to Buy from legitimate Share Owners at .0031 or .0032 ?
At 9:47 when the Ask Price rose to .0032, after the 14 million in Buying at 9:45, there were 16 million Shares available on the .0032 Ask Size.
Wondering how BIEL dropped to 29 with 16m Buys vs 10m Sells?
80 Percent of yesterday's 27 million share Volume was marked as Short Sales by the Regulation SHO Report.
It does not matter who the company is, if 80% of the Day's Volume is Short Sales the SP will drop.
Date...Symbol...Short vol...Total vol
20210528|BIEL|22168996||27457811
http://regsho.finra.org/FORFshvol20210528.txt
Regulation SHO is a 2005 SEC rule that governs short selling.
The regulation introduced the "locate" and "close-out" requirements aimed at curtailing naked short selling.
Despite the Regulation SHO Rules Brokers continue to violate Shorting Laws. If caught they pay a fine without admitting guilt and without disruption to their business.
SEC gives Morgan Stanley a $5 million slap over short sales
Sep 30, 2020
https://www.investmentnews.com/sec-gives-morgan-stanley-a-5-million-slap-over-short-sales-197614
FINRA fines Wolverine for short selling regulation violations
Posted by Maria Nikolova | May 25, 2021
https://fxnewsgroup.com/forex-news/regulatory/finra-fines-wolverine-for-short-selling-regulation-violations/
FINRA Fines Cantor Fitzgerald $2 Million for Regulation SHO Violations and Supervisory Failures
March 05, 2019
https://www.finra.org/media-center/news-releases/2019/finra-fines-cantor-fitzgerald-2-million-regulation-sho-violations-and
SEC Charges BNP Paribas with Violations of Regulation Sho
June 29, 2020
https://www.sec.gov/enforce/34-89177-s
FINRA Fines Deutsche Bank Securities Inc. $1.4 Million for Violating Regulation SHO and Short Interest Reporting Rules
https://www.finra.org/media-center/news-releases/2015/finra-fines-deutsche-bank-securities-inc-14-million-violating-reg-sho
How about 14 million in Buys to start the Day!!!
Time.......Last Price....Last Size
09:47:19 ET 0.0031 333301
09:46:42 ET 0.0031 1156699
09:46:40 ET 0.0031 10000
09:46:38 ET 0.0031 1000000
09:46:38 ET 0.0031 200000
09:46:38 ET 0.0031 300000
09:45:53 ET 0.003 1731113
09:45:45 ET 0.003 8585036
09:45:44 ET 0.003 2021337
A Rising Tide Lifts all Boats Pinhigh
US Consumer Education on PSWT has never been a possibility for BIEL on their own given the meager resources they have.
Enter the US OEM Partners; KT, DJO, SAI. Established companies with financial resources, Retail/Distribution Networks, Market clout and experience in Launching new products.
BIEL gets a steady cash flow by selling OEMs the Devices for their ActiPatch Enhanced Products and benefits from the mainstreaming of PSWT, paid for by the OEMs, in their ROW ActiPatch Sales, RecoveryRx Sales and Pipeline of Future Products.
This is a major Double Play for BIEL which can easily grow onto a Grand Slam with a few more Partners and Pipeline Products brought to Market.